Measuring Safety and Outcomes for the Use of Compassionate and Off-Label Therapies for Children, Adolescents, and Young Adults With Cancer in the SACHA-France Study.
Fiche publication
Date publication
juillet 2023
Journal
JAMA network open
Auteurs
Membres identifiés du Cancéropôle Est :
Pr CHASTAGNER Pascal, Pr ENTZ-WERLE Natacha
Tous les auteurs :
Berlanga P, Ndounga-Diakou LA, Aerts I, Corradini N, Ducassou S, Strullu M, de Carli E, André N, Entz-Werle N, Raimbault S, Roumy M, Renouard M, Gueguen G, Plantaz D, Reguerre Y, Cleirec M, Petit A, Puiseux C, Andry L, Klein S, Bodet D, Kanold J, Briandet C, Halfon-Domenech C, Nelken B, Piguet C, Saumet L, Chastagner P, Benadiba J, Millot F, Pluchart C, Schneider P, Thouvenin S, Gambart M, Serre J, Abbou S, Leruste A, Cayzac H, Gandemer V, Laghouati S, Vassal G
Lien Pubmed
Résumé
Innovative anticancer therapies for children, adolescents, and young adults are regularly prescribed outside their marketing authorization or through compassionate use programs. However, no clinical data of these prescriptions is systematically collected.
Mots clés
Child, Humans, Male, Adolescent, Young Adult, Infant, Child, Preschool, Adult, Female, Off-Label Use, Prospective Studies, Cohort Studies, Antineoplastic Agents, adverse effects, Brain Neoplasms, drug therapy
Référence
JAMA Netw Open. 2023 07 3;6(7):e2321568